APOE status (p<0.05) was found to moderate this effect, with APOE- ε4 carriers reflecting improvement while non-carriers were reflecting worsening of memory function, thereby suggesting that daily treatment with high dose (40 IU) intranasal insulin detemir modulated cognition for MCI or AD affected adults, with APOE-related differences in response to therapy [33]. This evidence concerns the gene INS and Alzheimer disease.